loading
Ionis Pharmaceuticals Inc stock is traded at $65.86, with a volume of 681.83K. It is up +0.47% in the last 24 hours and up +54.17% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$65.42
Open:
$65.35
24h Volume:
681.83K
Relative Volume:
0.29
Market Cap:
$10.49B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-21.66
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+2.80%
1M Performance:
+54.17%
6M Performance:
+141.12%
1Y Performance:
+68.24%
1-Day Range:
Value
$64.92
$66.14
1-Week Range:
Value
$62.72
$66.14
52-Week Range:
Value
$23.95
$66.14

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
Name
Ionis Pharmaceuticals Inc
Name
Phone
(760) 931-9200
Name
Address
2855 GAZELLE COURT, CARLSBAD, CA
Name
Employee
927
Name
Twitter
@ionispharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IONS's Discussions on Twitter

Compare IONS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
65.83 10.43B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
405.63 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.91 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.96 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
774.75 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
345.21 37.42B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-26-25 Upgrade Goldman Sell → Neutral
Sep-03-25 Upgrade BMO Capital Markets Market Perform → Outperform
Jul-31-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-01-25 Upgrade Barclays Equal Weight → Overweight
Apr-07-25 Initiated H.C. Wainwright Buy
Mar-31-25 Initiated Redburn Atlantic Neutral
Aug-02-24 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-24-24 Upgrade Leerink Partners Market Perform → Outperform
Jul-16-24 Resumed Jefferies Buy
Jun-14-24 Upgrade Bernstein Underperform → Mkt Perform
Apr-10-24 Upgrade Wolfe Research Peer Perform → Outperform
Jan-02-24 Upgrade BofA Securities Neutral → Buy
Oct-23-23 Upgrade BofA Securities Underperform → Neutral
Sep-29-23 Initiated Raymond James Strong Buy
Jul-31-23 Upgrade Citigroup Neutral → Buy
Jun-07-23 Resumed Piper Sandler Overweight
May-04-23 Upgrade Citigroup Sell → Neutral
Mar-21-23 Initiated Bernstein Underperform
Dec-21-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-22 Resumed Morgan Stanley Overweight
Jul-18-22 Resumed Oppenheimer Outperform
Mar-31-22 Resumed Piper Sandler Overweight
Mar-01-22 Initiated Citigroup Sell
Mar-01-22 Initiated Guggenheim Buy
Feb-01-22 Downgrade BofA Securities Buy → Underperform
Dec-14-21 Upgrade William Blair Mkt Perform → Outperform
May-07-21 Upgrade UBS Sell → Neutral
Mar-01-21 Upgrade Barclays Underweight → Equal Weight
Dec-16-20 Initiated UBS Sell
Dec-15-20 Upgrade Cowen Market Perform → Outperform
Sep-14-20 Resumed JP Morgan Neutral
Sep-02-20 Initiated The Benchmark Company Hold
Jun-01-20 Resumed Oppenheimer Outperform
May-13-20 Initiated RBC Capital Mkts Outperform
Mar-05-20 Initiated Citigroup Buy
Dec-13-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
Nov-07-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-10-19 Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18 Reiterated Stifel Hold
Aug-07-18 Reiterated Stifel Hold
May-08-18 Downgrade Evercore ISI Outperform → In-line
Oct-06-17 Resumed Goldman Sell
Aug-17-17 Initiated Evercore ISI Outperform
Aug-09-17 Reiterated Stifel Hold
Mar-10-17 Downgrade Goldman Neutral → Sell
Dec-28-16 Reiterated BMO Capital Markets Outperform
Dec-27-16 Reiterated Leerink Partners Mkt Perform
View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

pulisher
02:37 AM

Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Nigeria

02:37 AM
pulisher
Sep 30, 2025

What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in

Sep 30, 2025
pulisher
Sep 30, 2025

Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com

Sep 30, 2025
pulisher
Sep 30, 2025

Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 03:15:49 - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

Should you hold or exit Ionis Pharmaceuticals Inc. nowQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com

Sep 28, 2025
pulisher
Sep 27, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance

Sep 27, 2025
pulisher
Sep 26, 2025

IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus

Sep 26, 2025
pulisher
Sep 26, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat

Sep 26, 2025
pulisher
Sep 26, 2025

Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat

Sep 26, 2025
pulisher
Sep 26, 2025

Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener

Sep 26, 2025
pulisher
Sep 24, 2025

Ionis chalks up rare disease win with zilganersen - The Pharma Letter

Sep 24, 2025
pulisher
Sep 24, 2025

Is Ionis Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com

Sep 24, 2025
pulisher
Sep 24, 2025

Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK

Sep 24, 2025
pulisher
Sep 23, 2025

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com

Sep 23, 2025
pulisher
Sep 23, 2025

Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq

Sep 23, 2025
pulisher
Sep 23, 2025

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen

Sep 23, 2025
pulisher
Sep 23, 2025

A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm

Sep 23, 2025
pulisher
Sep 23, 2025

Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News

Sep 23, 2025
pulisher
Sep 23, 2025

Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits

Sep 23, 2025
pulisher
Sep 23, 2025

Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace

Sep 23, 2025
pulisher
Sep 23, 2025

IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria

Sep 23, 2025
pulisher
Sep 23, 2025

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace

Sep 23, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga

Sep 22, 2025
pulisher
Sep 22, 2025

Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq

Sep 22, 2025
pulisher
Sep 22, 2025

Ionis' brain disorder drug shows promise in clinical trial - TradingView

Sep 22, 2025

Ionis Pharmaceuticals Inc Stock (IONS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.00
price up icon 2.01%
$86.73
price up icon 2.26%
$31.54
price up icon 2.92%
$101.61
price up icon 3.03%
$146.85
price up icon 1.98%
biotechnology ONC
$345.21
price up icon 1.44%
Cap:     |  Volume (24h):